In this session, Dr. Rahimi, the scientific advisor of the group, presented the treatment protocol for symptomatic hyperuricemia (gout) according to the latest ACR guidelines, as well as the prescription of uric acid-lowering drugs in gout patients and asymptomatic hyperuricemia in high-risk patients, including those with moderate to severe kidney failure, pre-dialysis, and dialysis patients.
This scientific morning was attended by the President of the Iranian Rheumatology Association, Dr. Mohsen Soroush, along with esteemed rheumatology professors from Shariati Hospital Research Center:
- Dr. Tahereh Faezi
- Dr. Farhad Gharib Doost
- Dr. Mohsen Akhyani
- Dr. Sasan Fallahi
- Dr. Behrouz Yazdani
- Dr. Shahla Abolghasemi
- Dr. Soraya Shadmanfar
- Dr. Maryam Moghaddasi Jahromi
- Dr. Sara Vosoughian
- Dr. Majid Alikhani
- Dr. Masoumeh Akhlaghi
The fellowship of rheumatology and internal medicine residents was also held on Tuesday, 17 September 2024.
At the end of this session, the bioequivalence studies of Febix (Febuxostat), a product of Kimia Ara Company, with Adenuric, the brand from Menarini Company, were reviewed. The results showed that Febix, according to the bioequivalence criteria approved by the FDA, is therapeutically equivalent to the original Febuxostat brand of Menarini Company.”
